Repurposing a 50-Year-Old Deworming Drug: How Scientists Are Turning Niclosamide Into a Cancer Fighter

Cancer research has always had a knack for finding treatments in strange places. The Pacific yew tree gave us paclitaxel. Soil bacteria produced doxorubicin. Now scientists are looking at another unlikely source: niclosamide, a drug that has been sitting in medicine cabinets since the 1970s as a tapeworm treatment.

It started with a simple observation. Researchers noticed that this antiparasitic drug was killing cancer cells in petri dishes. That curiosity has since grown into a full drug development program. A team recently reported real progress in turning this old medication into a dual-targeting anticancer agent that works against breast and prostate cancers.

The Problem with a Good Idea

Niclosamide first got noticed when lab studies showed it could shut down multiple cancer pathways at once. It interferes with Wnt signaling, mTOR, NF-κB, CDK4/6, and JAK/STAT3—all pathways cancer cells need to survive. On paper, this makes it perfect for treating aggressive tumors that have stopped responding to single-target drugs.

But reality is messier. When you take niclosamide orally, barely any of it reaches your bloodstream. The drug does not dissolve well in water. The liver breaks it down quickly. It never achieves the concentrations needed to fight cancer throughout the body. This profile works fine for intestinal parasites, where the drug acts locally in the gut. For systemic cancer therapy, it is a dealbreaker.

A Chemical Makeover

The research team approached this with classic medicinal chemistry: keep the parts of the molecule that work, change the parts that do not. They converted niclosamide into Schiff bases—chemical compounds with an imine group (C=N) that can be decorated with different molecular attachments.

Medicinal chemists like Schiff bases because they are easy to make and allow lots of structural variations. By attaching different aromatic rings to the niclosamide core, the researchers hoped to improve solubility, metabolic stability, and binding to cancer proteins.

They made thirteen different compounds. Each had unique chemical appendages ranging from simple single-ring structures to complex bicyclic and tricyclic systems. The modifications included electron-donating groups like hydroxyl and isopropyl, halogens like bromine, and nitrogen-containing rings like pyrazole and quinoline.

Promising Results in the Lab

Testing these molecules against breast cancer lines (MCF-7 and MDA-MB-231) and prostate cancer cells (PC-3) showed dramatic improvements over the parent drug. Five of the thirteen compounds had substantial activity. Two stood out.

Compound 11, with its pyrazole ring, was exceptionally potent. Its IC50 values—the concentration needed to kill half the cancer cells—were 2.85 micromolar against MCF-7 breast cancer cells, 4.61 micromolar against the aggressive triple-negative MDA-MB-231 line, and 7.69 micromolar against PC-3 prostate cancer cells. These numbers rival or beat doxorubicin, a chemotherapy drug that has been in clinical use for decades.

Compound 8, with a brominated salicylaldehyde-derived structure, also showed strong activity with IC50 values in the 8-9 micromolar range against breast cancer lines. Several new compounds also showed better selectivity for cancer cells over normal cells compared to niclosamide itself, suggesting a wider therapeutic window.

Understanding the Mechanism

The researchers went beyond just counting dead cells. They wanted to know how these molecules worked. Through biochemical and cell biology experiments, they identified two key protein targets: JAK1 and CDK7.

JAK1 phosphorylates STAT3, a transcription factor that drives expression of genes promoting cell survival and proliferation in many cancers. CDK7 regulates both the cell cycle and gene transcription. Both are attractive but challenging drug targets. Inhibiting them simultaneously could produce synergistic anticancer effects.

Compound 11 inhibited both enzymes potently. Against JAK1, it achieved IC50 values between 0.01 and 0.10 micromolar across all three cancer cell lines—significantly better than niclosamide itself. For CDK7, it blocked over 80% of enzymatic activity in breast and prostate cancer cells, again beating the parent compound.

This dual-target activity produced the expected biological effects. When MCF-7 cells were treated with compound 11, they piled up in the G2/M phase of the cell cycle, unable to complete mitosis. The proportion of arrested cells jumped from around 13% to over 35%. Meanwhile, the sub-G1 population—a marker of apoptotic cell death—surged from 0.31% to nearly 21%.

Further experiments confirmed cell death was happening through classical apoptosis pathways. Caspases, the protease enzymes that execute programmed cell death, were activated. Caspase-1, -3, and -9 all showed elevated activity, with compound 11 outperforming niclosamide in several cases. Flow cytometry with Annexin V and propidium iodide staining showed most dying cells were undergoing apoptosis rather than necrosis.

Computer Models Support the Findings

To understand why these structural modifications improved activity, the researchers used computational methods. Molecular docking simulations showed compounds 8 and 11 fit into the active sites of both JAK1 and CDK7 with better binding energies than niclosamide. They formed hydrogen bonds with key amino acid residues—Leu959 in JAK1 and Lys41 and Met94 in CDK7—that are critical for enzyme function.

Molecular dynamics simulations, which model how protein-ligand complexes behave over time, provided more validation. Over 100 nanoseconds of simulation, the compound 11-JAK1 complex showed less structural fluctuation and more stable hydrogen bonding than the niclosamide complex. This suggests compound 11 binds more tightly and stays bound longer—both good properties for a drug candidate.

The computational analysis also addressed the original pharmacokinetic problem. ADME predictions (absorption, distribution, metabolism, excretion) indicated most new compounds follow Lipinski’s rules for drug-like molecules and have reasonable predicted oral bioavailability. While compound 11 itself showed slightly lower predicted absorption than niclosamide, several other derivatives in the series were projected to achieve 80-88% absorption rates.

What Comes Next

This research marks real progress in repurposing niclosamide for cancer treatment. By systematically modifying the chemical structure, the team identified lead compounds with substantially improved potency, maintained selectivity for cancer cells, and clearer understanding of their mechanism.

Compound 11 emerges as a strong candidate for further development. Its dual inhibition of JAK1 and CDK7 hits two distinct cancer cell vulnerabilities simultaneously, which could help prevent or delay drug resistance—a major problem with single-target therapies. That it outperforms doxorubicin in cell culture is noteworthy, though cell culture results do not always translate to living organisms.

The next stages must address several questions. How do these compounds behave in animal cancer models? Can they reach therapeutic concentrations in tumors without unacceptable toxicity to normal tissues? Will the improved pharmacokinetic properties predicted by computational models hold up in vivo? Can the chemical synthesis be scaled up economically if clinical trials succeed?

There is room for further optimization. While compound 11 shows excellent activity, its predicted oral absorption is slightly worse than some chemical cousins. The researchers note future work will focus on improving solubility and bioavailability while maintaining strong anticancer effects.

The Broader Context

This study fits into a larger trend: systematically exploring existing medications for new therapeutic uses. The advantages are obvious. These drugs have already passed human safety testing, which can accelerate development timelines. Manufacturing processes exist. And for off-patent drugs like niclosamide, treatment costs could stay affordable if new formulations prove effective.

The challenge, as this research shows, is that the original formulation is rarely optimal for the new indication. Niclosamide works fine for tapeworms at standard doses, but its pharmacokinetic limitations make it unsuitable for cancer therapy without modification. The Schiff base approach described here offers one path forward, but other strategies—prodrugs, nanoparticle formulations, or different chemical modifications—may also prove valuable.

What is encouraging is that the fundamental biology looks solid. Niclosamide really does hit multiple cancer-relevant targets. The issue has always been getting enough drug to the right place. With compounds like the ones in this study, that obstacle may finally be surmountable.

For breast and prostate cancer patients, particularly those whose tumors have developed resistance to standard therapies, new treatment options cannot come soon enough. These niclosamide derivatives are still early in the development pipeline, but they represent a promising addition to the growing arsenal of targeted anticancer agents. Sometimes the best solutions come from looking at old problems with fresh eyes—and new chemistry.

FAQ

What is niclosamide and why is it being studied for cancer?

Niclosamide is an FDA-approved antiparasitic medication that has been used since the 1970s to treat tapeworm infections. Researchers discovered that it can inhibit multiple cancer-promoting signaling pathways in laboratory studies, including Wnt/β-catenin, mTOR, NF-κB, and JAK/STAT3. This multi-target activity makes it potentially useful against cancers that have become resistant to single-target drugs. However, its poor absorption and rapid metabolism have prevented clinical use for cancer until now.

How did scientists improve niclosamide for cancer treatment?

The research team converted niclosamide into Schiff base derivatives—chemical compounds with an imine group that allows for structural modifications. By attaching different aromatic rings and functional groups to the niclosamide core, they created new molecules with better potency against cancer cells and improved drug-like properties. Thirteen different compounds were synthesized and tested.

Which cancers were tested in this study?

The researchers tested the new compounds against breast cancer (both hormone receptor-positive MCF-7 cells and triple-negative MDA-MB-231 cells) and prostate cancer (PC-3 cells). These represent common cancer types with significant unmet medical needs, particularly the aggressive triple-negative breast cancer subtype.

How effective were the new compounds compared to existing chemotherapy?

Compound 11, the most promising derivative, achieved IC50 values of 2.85 µM against MCF-7 breast cancer cells and 4.61 µM against MDA-MB-231 cells. These results rival or exceed the activity of doxorubicin, a standard chemotherapy drug that has been used clinically for decades. The parent drug niclosamide was significantly less potent in direct comparison.

What is a “dual-target” inhibitor and why does it matter?

A dual-target inhibitor blocks two different proteins involved in cancer growth simultaneously. In this study, compound 11 inhibits both JAK1 (a kinase that activates STAT3) and CDK7 (a regulator of cell cycle and transcription). Targeting multiple pathways at once makes it harder for cancer cells to develop resistance, which is a major problem with single-target therapies.

How does compound 11 kill cancer cells?

The compound works through several mechanisms. It arrests cancer cells in the G2/M phase of the cell cycle, preventing them from completing cell division. It also activates caspases (protease enzymes that execute programmed cell death), triggering apoptosis. Flow cytometry confirmed that treated cells predominantly die through this controlled cell death pathway rather than uncontrolled necrosis.

Are these compounds ready for human clinical trials?

Not yet. This research represents preclinical development—testing in cell cultures and computer models. Before human trials can begin, the compounds need to be tested in animal models to confirm efficacy, determine appropriate dosing, and assess safety. The researchers also plan further chemical optimization to improve solubility and oral bioavailability.

What are the advantages of repurposing existing drugs?

Drug repurposing offers several advantages over developing entirely new medications. The safety profile is already established from previous human use. Manufacturing processes exist. Development timelines can be shorter and less expensive. And for drugs like niclosamide that are off-patent, treatment costs could remain affordable if the new formulations prove effective.

What are Schiff bases and why were they chosen for this modification?

Schiff bases are organic compounds containing a carbon-nitrogen double bond (C=N). They are attractive to medicinal chemists because they are relatively easy to synthesize and can accommodate a wide variety of structural modifications. This flexibility allowed the researchers to test many different chemical variations to find the most potent anticancer derivatives.

What challenges remain before these compounds could become cancer drugs?

Several hurdles remain. The compounds need to demonstrate efficacy and safety in animal studies. Their pharmacokinetic properties—how they are absorbed, distributed, metabolized, and excreted—need to be characterized in living organisms. Manufacturing must be scaled up. And ultimately, they must prove effective and safe in human clinical trials, which typically takes several years even for repurposed drugs.